Interestingly, the SURPASS‐1 trial, tirzepatide as monotherapy for early T2D, demonstrated significant improvements in insulin sensitivity and multiple biomarkers of pancreatic beta‐cell function, and potentially preservation.122. This evidence concerns the gene INS and type 2 diabetes mellitus.